Arbor Rapha Capital Bioholdings I EBIT

The latest EBIT for ARCK is $-450B as of September 2022. That is below the sector sector average of $-6.4M. Investors often review this figure alongside Arbor Rapha Capital Bioholdings I's historical trend and sector peers before judging valuation or financial health.

Against its sector companies, ARCK currently prints $-450B for EBIT, while the sector average sits near $-6.4M. That is roughly 6960196.5% below the sector mean. Large gaps often invite a closer look at Arbor Rapha Capital Bioholdings I's growth, margins, and balance sheet.

A EBIT figure of $-450B for ARCK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-6.4M. Explore the charts below for those layers of context.

After noting ARCK's EBIT ($-450B), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.